Design of α-S-Neoglycopeptides Derived from MUC1 with a Flexible and Solvent-Exposed Sugar Moiety
- Rojas-Ocáriz, V. 3
- Compañón, I. 3
- Aydillo, C. 23
- Castro-Loṕez, J. 1
- Jiménez-Barbero, J. 46
- Hurtado-Guerrero, R. 15
- Avenoza, A. 3
- Zurbano, M.M. 3
- Peregrina, J.M. 3
- Busto, J.H. 3
- Corzana, F. 3
-
1
Universidad de Zaragoza
info
-
2
University of Copenhagen
info
-
3
Universidad de La Rioja
info
-
4
Centro de Investigaciones Biológicas
info
-
5
Fundación Agencia Aragonesa para la Investigación y el Desarrollo
info
Fundación Agencia Aragonesa para la Investigación y el Desarrollo
Zaragoza, España
-
6
Ikerbasque, Fundación Vasca para la Ciencia
info
ISSN: 0022-3263
Año de publicación: 2016
Volumen: 81
Número: 14
Páginas: 5929-5941
Tipo: Artículo
beta Ver similares en nube de resultadosOtras publicaciones en: Journal of Organic Chemistry
Proyectos relacionados
Resumen
The use of vaccines based on MUC1 glycopeptides is a promising approach to treat cancer. We present herein several sulfa-Tn antigens incorporated in MUC1 sequences that possess a variable linker between the carbohydrate (GalNAc) and the peptide backbone. The main conformations of these molecules in solution have been evaluated by combining NMR experiments and molecular dynamics simulations. The linker plays a key role in the modulation of the conformation of these compounds at different levels, blocking a direct contact between the sugar moiety and the backbone, promoting a helix-like conformation for the glycosylated residue and favoring the proper presentation of the sugar unit for molecular recognition events. The feasibility of these novel compounds as mimics of MUC1 antigens has been validated by the X-ray diffraction structure of one of these unnatural derivatives complexed to an anti-MUC1 monoclonal antibody. These features, together with potential lack of immune suppression, render these unnatural glycopeptides promising candidates for designing alternative therapeutic vaccines against cancer. © 2016 American Chemical Society.